Cargando…

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis

BACKGROUND: Psoriasis is a common, chronic, immune-mediated inflammatory skin disease with increased epidermal proliferation. The objective of this review was to systematically identify the evidence and perform a network meta-analysis (NMA) to estimate the relative efficacy of secukinumab (SEC) agai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Ran, Wang, Xiaolun, Shu, Min, Das, Jaydeep, Kalra, Manik, Wang, Zhidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Meta Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850822/ https://www.ncbi.nlm.nih.gov/pubmed/34882622 http://dx.doi.org/10.1097/CM9.0000000000001817

Ejemplares similares

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
por: Wang, Yuqian, et al.
Publicado: (2023)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis
por: Zhao, Zheng, et al.
Publicado: (2022)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Yang, Seungwon, et al.
Publicado: (2021)

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab
por: Tichy, Martin
Publicado: (2019)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Infliximab for the treatment of plaque psoriasis
por: Gall, Jennifer S, et al.
Publicado: (2008)

Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis
por: Zhou, Hang, et al.
Publicado: (2020)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
por: Mantovani, Lorenzo, et al.
Publicado: (2016)

The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet’s disease: a systematic review and meta-analysis
por: Mohammed, Reem Hamdy A, et al.
Publicado: (2023)

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study
por: Ding, Yangfeng, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study
por: Gottlieb, A.B., et al.
Publicado: (2021)

Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis
por: Tian, Fangyuan, et al.
Publicado: (2019)

Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis
por: Bai, Fan, et al.
Publicado: (2017)

Infliximab in the treatment of plaque type psoriasis
por: Saraceno, Rosita, et al.
Publicado: (2009)

Cytokine Modulators in Plaque Psoriasis – A Review of Current and Prospective Biologic Therapeutic Approaches
por: Strychalski, Marisa L., et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
por: Zhao, Yan, et al.
Publicado: (2021)

Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study
por: Tamer, Funda, et al.
Publicado: (2020)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023)

Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials
por: Zhang, Jing-Zhan, et al.
Publicado: (2020)

Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis
por: Zou, Qian, et al.
Publicado: (2021)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
por: Galica, Katarzyna, et al.
Publicado: (2020)

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
por: Körber, Andreas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_so47ml2497kgqbatsk01aeblsi